Advancements in itch therapeutics have evolved rapidly, offering patients with various itch-driven diseases multiple options that target the source of their itch. Itch exists on a spectrum, according ...

Barclays (LON: BARC) has initiated coverage on Galderma Group AG (SIX: GALD) and Zealand Pharma (NASDAQ: ZEAL) with Overweight ratings, citing distinct growth dri ...

For Galderma, the analysts point to the strong commercial launch of Nemluvio, its recently approved therapy for prurigo nodularis (PN) and atopic dermatitis (AD).

The antibody is in a phase 2b trial in prurigo nodularis – a rare and highly debilitating skin disease which causes intense itching and which has no approved therapies, although Sanofi has filed ...

Sanofi gets a win for its oral BTK inhibitor rilzabrutinib in chronic hive disorder CSU, setting up a phase 3 programme as it chases after Novartis’ remibrutinib in this indication.

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years ...